3 completed, 3 recruiting, 3 unknown, 1 not yet recruiting. 4 Phase 1, 3 Not applicable, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Not yet recruiting 1, Unknown 1 |
| Not applicable | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Haematologic Disease: new trials by email Literature Review of Haematologic Disease trials Research Report on Haematologic Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dietitian-Driven Unified Nutritional Care Model (ADDUCE) Dietitian-driven nutritional care model, Current practice nutritional care - Hospitalized Adult Patients, Inpatient Internal Medicine Patients | Not applicable | Recruiting | Gødstrup Hospital | 216 | 2026-08-11 | 2026-08-31 |
| A Clinical Study to Map the HLA Genomic Region in the Greek Population Healthy, Respiratory Disease | Unknown | Athens LifeTech Park | 12000 | 2023-12-12 | 2024-01-26 | |
| A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone - Multiple Myeloma, Neoplasms | Phase 1 / Phase 2 | Recruiting | Hellenic Society of Hematology | 36 | 2023-07-14 | 2023-10-24 |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Not yet recruiting | Hellenic Society of Hematology | 48 | 2022-10-20 | 2022-10-17 |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide - Multiple Myeloma, Neoplasms | Phase 1 / Phase 2 | Unknown | Hellenic Society of Hematology | 36 | 2022-04-13 | 2023-12-01 |
| Horse-assisted Interventions in an Oncological Centre Horse-Assisted Intervention (HAI) - Breast Cancer, Oncologic Disorders | Not applicable | Completed | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 28 | 2021-06-14 | 2026-10-01 |
| AAV Gene Therapy Screening/Observational Protocol (ECLIPSE) Hemophilia B, Blood Coagulation Disorders, Inherited | Completed | Spur Therapeutics | 37 | 2020-02-14 | 2022-11-04 | |
| Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation CTL 19 - Haematologic Disease | Phase 1 | Recruiting | Nantes University Hospital | 6 | 2020-02-09 | 2026-01-26 |
| Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies clinical data and sample collection - Haematologic Disease, Haematological Malignancy | Unknown | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2000 | 2020-01-07 | 2024-07-01 | |
| The Influence of Nursing Technique Applied at the Central Venous Catheter Insertion Site Upon the Incidence of Infection CHG technique, HMG technique - Surgery, Multiorgan Failure | Not applicable | Completed | University Hospital Ostrava | 221 | 2016-02-01 | 2019-03-14 |
Hematologic Diseases (10) · Blood Protein Disorders (3) · Corneal Diseases (3) · Multiple Myeloma (3) · Neoplasms (3) · Neoplasms, Plasma Cell (3) · Paraproteinemias (3) · Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Breast Neoplasms (1) · Cardiovascular Diseases (1) · Collagen Diseases (1) · Communicable Diseases (1) · Gastrointestinal Diseases (1) · Hematologic Neoplasms (1)
Hemic and Lymphatic Diseases (10) · Hemorrhagic Disorders (4) · Cardiovascular Diseases (3) · Eye Diseases (3) · Hemostatic Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Vascular Diseases (3) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2)
Dexamethasone (3) · Lenalidomide (2) · daratumumab (2) · Immunotherapy, Adoptive (1) · Specimen Handling (1) · nirogacestat (1) · pomalidomide (1)
Hellenic Society of Hematology (3) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (2) · Athens LifeTech Park (1) · Gødstrup Hospital (1) · Nantes University Hospital (1) · Spur Therapeutics (1) · University Hospital Ostrava (1)
Greece (3) · Italy (3) · France (2) · Australia (1) · Austria (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Ireland (1) · Netherlands (1) · South Africa (1) · Turkey (Türkiye) (1) · United Kingdom (1) · United States (1)
Evangelos Terpos, Prof (3) · Alessandro Lucchesi, MD (1) · Efi Giannopoulou (1) · Giovanni Martinelli, Prof (1) · Marianne Boll Kristensen, RD, PhD (1) · Pratima Chowdary, Dr (1)